clinical trial · NCT06068465
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Tasly Pharmaceutical Group Co., Ltd·phase3·completed·n = 248
Parkinson's Disease Psychosispimavanserin tartrateplacebo
brief summary
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
started
Sep 27, 2024
primary completion
Feb 1, 2026
completion
Feb 1, 2026
last updated
Feb 27, 2026
official title
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol